Amgen Inc. and Pfizer Inc. are two of the largest pharmaceutical companies in the world, yet their current investment profiles diverge meaningfully. Amgen is a biotechnology heavyweight whose growth drivers are accelerating even amid patent expirations, while Pfizer is a diversified drugmaker working through a post-pandemic transition marked by cost cuts and a shift toward oncology and obesity. This stock comparison is relevant for investors weighing growth momentum against dividend income, and for traders assessing relative performance and market positioning between two large-cap healthcare names.
AMGN (Amgen Inc.) is a leading biotechnology company focused on oncology, cardiovascular disease, inflammation, and rare disease. In recent weeks, the stock has traded near the upper end of its 52-week range, with a market capitalization of roughly $250 billion and a trailing-twelve-month revenue gain of about 9%.
Sentiment has been supported by stronger-than-expected quarterly results in which sales topped $10 billion and adjusted earnings beat consensus, prompting management to raise its full-year revenue and earnings outlook. Growth has been broad-based: Repatha, Evenity, and rare-disease therapy Uplizna all posted sharp increases, helping offset biosimilar-driven pressure on Prolia. The company also announced positive Phase 3 data across its pipeline, while continuing to advance MariTide, its investigational obesity treatment. These factors have contributed to strong year-to-date momentum and a premium valuation relative to some historical measures.
PFE (Pfizer Inc.) is a global pharmaceutical and vaccine company with franchises spanning oncology, immunology, cardiovascular disease, and infectious disease. In recent market activity, the stock has climbed about 20% year-to-date and recently reached a 52-week high, aided by a forward dividend yield near 6%.
Pfizer's recovery reflects improving sentiment around its turnaround, but the path has been uneven. Declining COVID-19 product sales for Comirnaty and Paxlovid continue to weigh on results, and a recent quarter included non-cash write-downs tied to a late-stage lung cancer trial and the removal of a revenue forecast for Oxbryta. Management has emphasized cost reductions of more than $7 billion over three years, with additional savings planned, while growth from products such as Eliquis, Padcev, Lorbrena, and Nurtec has helped offset headwinds. Investors are also watching upcoming patent expirations on key blockbusters, which create a multi-year transition risk.
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, but only a curated selection earns a place in the Trending AI Robots section. This page highlights the strategies considered best suited to current market conditions, spanning varied trading styles, timeframes, risk profiles, and performance statistics. Because each bot applies a distinct set of rules and focuses on different tickers, traders can compare approaches that range from short-term swing signals to longer-horizon trend systems. Reviewing the Trending AI Robots can help investors identify automated strategies aligned with their own objectives and risk tolerance.
The two companies differ sharply in business model emphasis and near-term trajectory. Amgen leans toward innovative biologics and a growing biosimilars portfolio, and its current narrative is one of accelerating growth driven by six key product areas. Pfizer, by contrast, remains a diversified giant whose near-term story centers on offsetting COVID-19 revenue declines and preparing for loss of exclusivity on Eliquis and Ibrance.
On relative performance, Amgen has posted the stronger recent returns and more consistent earnings momentum, while Pfizer offers a meaningfully higher dividend yield but trades at a higher trailing price-to-earnings multiple following profit compression. Growth drivers also differ: Amgen is betting on cardiovascular, bone-health, rare-disease, and obesity assets, whereas Pfizer is prioritizing oncology (led by the Seagen acquisition) and a renewed push into obesity through Metsera. Risk factors diverge as well — Amgen faces biosimilar competition and pipeline execution risk, while Pfizer contends with a patent cliff and the possibility of further write-downs.
Weighing observable factors such as trend consistency, earnings momentum, guidance increases, and relative positioning, Tickeron's AI would currently favor AMGN over PFE. Amgen's combination of rising revenue, diversified growth drivers, and constructive sentiment gives it a more consistent and stable trend profile, while Pfizer's appeal rests more heavily on dividend yield and a turnaround that remains subject to patent-expiration and write-down risks. This assessment reflects probabilities based on current data rather than a guaranteed outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 36 cases where AMGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 147 of 271 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 22 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In 29 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 38%.
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 19 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
PFE saw its Momentum Indicator move below the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 57 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 64%.
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 24 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
PFE moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 153 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
PFE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 94 of 185 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 4 | 100 | |
SMR RATING 1..100 | 15 | 83 | |
PRICE GROWTH RATING 1..100 | 40 | 47 | |
P/E GROWTH RATING 1..100 | 35 | 4 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (79) in the Biotechnology industry is in the same range as PFE (96) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
AMGN's Profit vs Risk Rating (4) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (40) in the Biotechnology industry is in the same range as PFE (47) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as AMGN (35) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 47% | 3 days ago 61% |
| Stochastic ODDS (%) | 3 days ago 60% | 3 days ago 53% |
| Momentum ODDS (%) | 3 days ago 38% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 41% | 3 days ago 56% |
| TrendWeek ODDS (%) | 3 days ago 50% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 48% | 3 days ago 53% |
| Advances ODDS (%) | 14 days ago 62% | 12 days ago 54% |
| Declines ODDS (%) | 3 days ago 46% | 3 days ago 56% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 50% |
| Aroon ODDS (%) | 3 days ago 54% | 3 days ago 51% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
AMGN (@Pharmaceuticals: Major) experienced а -5.91% price change this week, while PFE (@Pharmaceuticals: Major) price change was -5.16% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -12.82%. For the same industry, the average monthly price growth was -9.89%, and the average quarterly price growth was -5.74%.
AMGN is expected to report earnings on Feb 09, 2027.
PFE is expected to report earnings on Feb 02, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.15% | ||
| PFE - AMGN | 51% Loosely correlated | -0.51% | ||
| GILD - AMGN | 48% Loosely correlated | -0.06% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.94% | ||
| BIIB - AMGN | 47% Loosely correlated | +1.00% | ||
| MRK - AMGN | 47% Loosely correlated | +0.69% | ||
More | ||||
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.51% | ||
| BMY - PFE | 60% Loosely correlated | +0.79% | ||
| AMGN - PFE | 53% Loosely correlated | -0.15% | ||
| GSK - PFE | 51% Loosely correlated | -0.13% | ||
| NVS - PFE | 50% Loosely correlated | -0.50% | ||
| BIIB - PFE | 46% Loosely correlated | +1.00% | ||
More | ||||